...
首页> 外文期刊>Stem cell research >Human induced pluripotent stem cell line with cytochrome P450 enzyme polymorphism (CYP2C19*2/CYP3A5*3C) generated from lymphoblastoid cells - ScienceDirect
【24h】

Human induced pluripotent stem cell line with cytochrome P450 enzyme polymorphism (CYP2C19*2/CYP3A5*3C) generated from lymphoblastoid cells - ScienceDirect

机译:人类诱导的多能干细胞系具有从淋巴细胞样细胞生成的细胞色素P450酶多态性(CYP2C19 * 2 / CYP3A5 * 3C)-ScienceDirect

获取原文
           

摘要

Cytochrome P450 (CYP) comprises a superfamily of monooxygenase responsible for the metabolism of xenobiotics and approximately 75% of drugs in use today. Thus, genetic polymorphisms in CYP genes contribute to interindividual differences in hepatic metabolism of drugs, affecting on individual drug efficacy and may cause adverse effects. Here, we generated a human induced pluripotent stem cell (hiPSC) line with pharmacologically important traits (CYP2C19*2/CYP3A5*3C), which are highly polymorphic in Asian from lymphoblastoid cells. This hiPSC line could be a valuable source for predicting individual drug responses in the drug screening process that uses hiPSC-derived somatic cells, including hepatocytes.
机译:细胞色素P450(CYP)包含负责异种生物素代谢的单加氧酶超家族,以及目前使用的大约75%的药物。因此,CYP基因的遗传多态性导致药物肝代谢的个体差异,影响单个药物的疗效并可能引起不良反应。在这里,我们生成了具有药理学重要特征(CYP2C19 * 2 / CYP3A5 * 3C)的人诱导多能干细胞(hiPSC)品系,其在亚洲人的淋巴母细胞中具有高度多态性。该hiPSC品系可能是预测使用hiPSC衍生的体细胞(包括肝细胞)的药物筛选过程中单个药物反应的有价值的来源。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号